CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2 Genes in Gastric Adenocarcinoma Patients
- 12 Downloads
Gastric cancer is an aggressive disease which is the fourth prevalent malignancy in the world. Beside the genetic factors, epigenetic alterations such as promoter CpG island hyper methylation are involved in the emergence of gastric cancer. Herein, we investigated the methylation status of CDH11, EphA5, and HS3ST2 genes in patients with and without gastric adenocarcinoma for the first time.
In the study 40 paraffin-embedded tissue sections from gastric adenocarcinoma patients and 40 specimens from patients with functional dyspepsia were taken. DNA extraction was performed using a modified salting out method. Epizen DNA methylation kit was used to the bisulfite DNA conversion. The methylation status of CDH11, EphA5, and HS3ST2 genes were analyzed by methylation-specific PCR (MSP) technique.
Among the 80 specimens, 71 DNA samples were achieved (34 gastric adenocarcinoma patients and 37 control patients). The results showed that CDH11, EphA5, and HS3ST2 genes are methylated in 28 (82.45%), 19 (55.88%), and 26 (76.47%) of 34 DNA samples from gastric adenocarcinoma patients, respectively, whereas, these genes are methylated in 7 (18.91%), 9 (24.32%) and 7 (18.91%) of 37 samples from noncancerous patients, respectively. Statistical analyses using a chi-squared test showed that there is a statistically significant difference in methylation level of CDH11, EphA5, and HS3ST2 genes between gastric cancer and uncancerous patients (p < 0.05).
To the best of our knowledge, this is the first report on methylation of CDH11, EphA5, and HS3ST2 promoters’ in gastric adenocarcinoma patients using MSP. Identification of novel cancer-related molecular mechanisms can be useful in detection of new treatment strategies.
KeywordsGastric adenocarcinoma Hyper methylation MSP CDH11 EphA5 HS3ST2
This work was funded and supported by Liver and Gastrointestinal Diseases Research Center of Tabriz University of Medical Sciences (Grantnumber: 61877) and Molecular Medicine Research Center, Bio‐medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Compliance with Ethical Standards
The present study was approved by the Ethics and Research Committees of the Tabriz University of Medical Sciences.
Conflict of Interest
The authors report no conflicts of interest in this work.
- 2.Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer. In: Gastric cancer: Springer; 2015. p. 23–34.Google Scholar
- 4.Patel TN, Roy S, Ravi R. Gastric cancer and related epigenetic alterations. Ecancermedicalscience. 2017:11.Google Scholar
- 5.Takeshima H, Yamada H, Ushijima T. Cancer epigenetics: aberrant DNA methylation in cancer diagnosis and treatment. In: Oncogenomics: Elsevier; 2019. p. 65–76.Google Scholar
- 6.Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. In: Cancer epigenetics: Springer; 2015. p. 3–25.Google Scholar
- 8.Lim DH, Maher ER. DNA methylation: a form of epigenetic control of gene expression. Obstet Gynaecol. 2010;12(1):37–42.Google Scholar
- 23.Leontiou CA, Hadjidaniel MD, Mina P, Antoniou P, Ioannides M, Patsalis PC. Bisulfite conversion of DNA: performance comparison of different kits and methylation quantitation of epigenetic biomarkers that have the potential to be used in non-invasive prenatal testing. PLoS One. 2015;10(8):e0135058.CrossRefGoogle Scholar
- 24.Organization WH. Global cancer rates could increase by 50% to 15 million by 2020. In: Global cancer rates could increase by 50% to 15 million by 2020; 2003.Google Scholar
- 25.Ferreira HJ, Esteller M. CpG islands in cancer: heads, tails, and sides. In: CpG Islands: Springer; 2018. p. 49–80.Google Scholar